Sling Therapeutics’ convenient oral small molecule linsitinib is in a Phase 2b trial for thyroid eye disease (TED), and works by inhibiting the validated IGF-1R target. Linsitinib has established a safety profile through treatment of over 800 patients.  It is also being investigated for the treatment of additional autoimmune and rare diseases.

We are focused on bringing additional treatment options to patients, as well as the ophthalmology, endocrinology, and rare disease communities. We welcome the opportunity for collaboration in this mission.